← Back to Screener
Calidi Biotherapeutics, Inc. (CLDI)
Price$0.18
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-102.52%
Price vs S&P 500 (4W)-19.48%
VGM Score14.25
Market Capitalization$3.57M
All Metrics
Book Value / Share (Quarterly)$0.42
P/TBV (Annual)1.78x
Cash Flow / Share (Quarterly)$-1.56
Price vs S&P 500 (YTD)-95.12%
EPS (TTM)$-4.00
10-Day Avg Trading Volume2.43M
EPS Excl Extra (TTM)$-4.00
EPS (Annual)$-65.49
ROI (Annual)2.62%
Cash / Share (Quarterly)$0.56
ROA (Last FY)-291.61%
EBITD / Share (TTM)$-2.76
Cash Flow / Share (Annual)$-2.97
P/B Ratio0.72x
P/B Ratio (Quarterly)0.53x
Net Income / Employee (Annual)$-1,007,400
Net Interest Coverage (TTM)-26.32x
ROA (TTM)-181.96%
EPS Incl Extra (Annual)$-65.49
Current Ratio (Annual)1.59x
Quick Ratio (Quarterly)1.79x
3-Month Avg Trading Volume2.95M
52-Week Price Return-95.91%
Tangible BV / Share (Quarterly)$3.16
52-Week High$19.20
EPS Excl Extra (Annual)$-65.49
CapEx CAGR (5Y)-19.32%
26-Week Price Return-86.59%
Quick Ratio (Annual)1.48x
13-Week Price Return-78.13%
Total Debt / Equity (Annual)0.23x
Current Ratio (Quarterly)1.92x
Enterprise Value$-2.16M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.78
3-Month Return Std Dev131.62%
Net Income / Employee (TTM)$-656,100
ROE (Last FY)2.80%
Net Interest Coverage (Annual)-113.75x
EPS Basic Excl Extra (Annual)$-65.49
P/FCF (TTM)47.14x
Total Debt / Equity (Quarterly)0.18x
EPS Incl Extra (TTM)$-4.00
ROI (TTM)-343.05%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.77
Price vs S&P 500 (52W)-124.11%
Year-to-Date Return-84.19%
5-Day Price Return5.23%
EPS Normalized (Annual)$-65.49
Month-to-Date Return-21.94%
Cash Flow / Share (TTM)$-0.66
EBITD / Share (Annual)$-65.16
LT Debt / Equity (Annual)0.16x
LT Debt / Equity (Quarterly)0.12x
EPS Basic Excl Extra (TTM)$-4.00
P/TBV (Quarterly)2.12x
P/B Ratio (Annual)2.23x
Book Value / Share (Annual)$0.52
Price vs S&P 500 (13W)-87.88%
Beta1.37x
P/FCF (Annual)675.84x
ROE (TTM)-438.03%
52-Week Low$0.16
mGradeF
vgmGradeF
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.29
4.29
4.29
4.29
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CLDICalidi Biotherapeutics, Inc. | — | — | F | $0.18 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Calidi Biotherapeutics is a clinical-stage immuno-oncology company developing allogeneic stem cell therapies that deliver oncolytic viruses to treat cancer. Its pipeline includes CLD-101 for high-grade gliomas, CLD-201 for solid tumors, and CLD-400 for lung cancer and metastatic tumors, with CLD-301 in discovery research.